On October 12, 2026, Nature Medicine published a study from Weizmann Institute of Science researchers that analysed more than 300 million laboratory tests from over one million women in the U.S. and Israel, collected between 1999 and 2024. The finding, in senior author Uri Alon's words to Scientific American: "Menopause is not a slow part of aging. It's an abrupt, body-wide transition across bone, liver, kidney, blood chemistry, fats, and more." The researchers describe this as a "physiological cliff" around the final menstrual period.

Why It Matters

This study supports the **timing** argument that menopause-care companies have been making mostly from anecdote: that the window around the final period is a distinct clinical event and not just a gradual slide. It comes a week after the American College of Physicians [made hormone therapy first-line for menopause symptoms](/stories/acp-menopause-hormone-therapy-first-line), and the same week that [Hers launched menopause care in Australia](/stories/hims-australia-pilot-rebrand) and [Allara raised $30M](/stories/allara-30m-womens-hormonal-care) for integrated hormonal care. Expect telehealth marketing to cite "the cliff" within weeks. Expect clinicians to point out that the study is observational and does not show that starting therapy early prevents anything. Supply has not kept up with this demand. The *Toronto Star*'s consumer-affairs desk reported on October 12 on recurring **estrogen-patch shortages** in Canada. Unmanaged menopause symptoms are estimated to cost the Canadian economy **$3.5 billion a year**, and Mount Sinai menopause chair Dr. Wendy Wolfman put it this way: "If you have diabetes, you get insulin. But nobody seems to think estrogen is important." For sexual wellness, the systemic picture includes the genitourinary symptoms (dryness, pain, reduced arousal) that drive demand for lubricants, moisturisers, vaginal estrogen and devices. A transition that is abrupt rather than gradual means that demand arrives suddenly too, which is an argument for brands to reach women before the final period, not after.

The pattern is a slope followed by a step. Alon told Newsweek the team saw "gradual changes starting about a decade before menopause on average and accelerating in the years before the final menstrual period and then a jump at the final period," apparently within about a year of it. The hormonal lead-up starts much earlier: anti-Müllerian hormone and estradiol begin declining quickly roughly 15 and 12 years beforehand, and FSH begins rising about 14 years before. In the U.S. data, 52 of 90 lab tests showed abrupt shifts, most of them in the direction of higher disease risk, including a jump toward bone loss. Some changes went the other way: iron and haemoglobin improved, probably because monthly bleeding stopped. When the team ran the same analysis on men with the same age distribution, the jumps disappeared. In Alon's words, "they show changes of gradual aging over decades."

The finding most relevant to industry: women on menopausal hormone therapy showed smaller jumps in several systems, especially bone, liver and kidney. The authors stress that this is observational. Alon suggests some women might benefit from starting hormone therapy earlier, before the final period, but says more research is needed to test that.

Sources

Update — 2026-10-14

Initial entry — story first created.